His h-index has reached the important level of 50 with more than 500 citations per year.
ORLANDO, FL, April 24, 2024 /24-7PressRelease/ -- Jacques Turgeon has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Drawing on years of experience in pharmacy, education, and scientific research, Dr. Turgeon excels as the co-founder and chief executive officer of GalenusRx. In this capacity, he oversees product development and research, remains current regarding new drugs and potential side effects, manages business development, and seeks investment opportunities. Before obtaining his current role, he was the chief scientific officer of Tabula Rasa HealthCare, Inc. During his career, he filled various administrative and research positions as CEO Centre hospitalier de l'Université de Montréal (CHUM), Director of the Research Center CHUM (CRCHUM), vice-president research Université de Montréal, Dean College of Pharmacy Université de Montréal, Director of research Quebec Heart Institute, Laval University. He is Professor Emeritus Université de Montréal, a Fellow of the Canadian Academy of Health Sciences, and an international Fellow Académie de médecine, France.
Due to his vast breadth of knowledge, Dr. Turgeon has contributed to many publications and played a significant role in shaping the future of the field through his mentorship. His h-index has reached the important level of 50 with more than 500 citations per year. His publications, including "Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy," "Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine," "Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval," "Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs," and "Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism," are a testament to his expertise in various fields. Likewise, he has co-authored numerous review articles such as "The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart", "Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice", "Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-COA reductase inhibitors," "The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition," and "Multidrug Interactions: Why Do They Occur and How to Handle?" Alongside his various publications, Dr. Turgeon has overseen several master's degree and doctoral degree students through their dissertations, a role that he takes great pride in and that has earned him the appreciation of many in the field.
Dr. Turgeon's academic journey is a testament to his commitment to professional growth. He holds a Bachelor of Pharmacy, a Master of Sciences in pharmacokinetics and drug metabolism, and a PhD in the same disciplines from Laval University. He further expanded his knowledge through a postdoctoral fellowship in pharmacogenomics and cardiac electrophysiology at Vanderbilt University's Department of Clinical Pharmacology. His dedication to staying current in the field is evident through his affiliations with the American Society for Clinical Pharmacology and Therapeutics, the Canadian Academy of Health Sciences, and the Academy of Medicine in France.
Given his professional achievements, Dr. Turgeon received the Prix Bâtisseur du CRCHUM, the Pharmacien de Coeur et d'Action Award from L'Actualité Pharmaceutique, and several awards for his excellence in teaching. While his career has been filled with highlights, he takes the most pride in holding various administrative positions that led to the development of the first entry level PharmD degree in Canada, the construction of several buildings, including a $50 million building for the College of Pharmacy in Montreal, and a $475 million research center (CRCHUM). The cornerstone of his success lies with his mentors, exposure to Nobel Prize winners, and perseverance. In the next five years, Dr. Turgeon intends to continue developing and implementing strategies to help manage the drug regimen of people taking multiple medication and continue working on a product that reduces hospitalizations, emergency room visits, and adverse drug event, the fourth leading cause of death.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #